CF PharmTech, Inc. Class H

As of December 31, 2025, CF PharmTech, Inc. Class H carries a market capitalization of 14.42B, placing it among publicly traded companies globally. Its enterprise value stands at 13.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CF PharmTech, Inc. Class H's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, CF PharmTech, Inc. Class H has 411.91M shares outstanding.

As of December 31, 2025, CF PharmTech, Inc. Class H trades at a trailing price-to-earnings ratio of 4,779.42. The price-to-sales ratio is 27.46, and the price-to-book ratio stands at 8.82.

As of December 31, 2025, CF PharmTech, Inc. Class H trades at an EV/EBITDA multiple of 220.73 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 28.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.85B versus a market cap of 14.42B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, CF PharmTech, Inc. Class H maintains a current ratio of 4.59, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.91, indicating elevated leverage, while an interest coverage ratio of 22.20 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, CF PharmTech, Inc. Class H posted a return on equity (ROE) of 0.21, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.16, measuring how efficiently the asset base is converted into earnings. The company generates approximately 891,386.35 in revenue per employee across its workforce of 540.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.49 indicates how many times CF PharmTech, Inc. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, CF PharmTech, Inc. Class H recorded an income tax benefit of -17.69M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -14.92M and 2.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, CF PharmTech, Inc. Class H's stock has declined approximately 81.11% over the past 52 weeks. The 50-day moving average sits at 10.61, while the 200-day moving average is 21.24.

Over the twelve months ended December 31, 2025, CF PharmTech, Inc. Class H generated 481.35M in revenue and converted that into 2.77M in net income, yielding earnings per share of 0.01. EBITDA reached 62.76M, while operating income came in at -7.67M.

As of December 31, 2025, CF PharmTech, Inc. Class H holds 726.98M in cash and equivalents against 161.99M in total debt, resulting in a net debt position of -303.36M. Total book value stands at 1.63B, with working capital of 774.79M providing operational flexibility.

CF PharmTech, Inc. Class H produced -122.75M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -168.19M in capital expenditures, free cash flow totaled -290.94M - equivalent to -0.77 per share.

Over the twelve months ended December 31, 2025, CF PharmTech, Inc. Class H posted a gross margin of 75.82, reflecting its pricing power and cost economics. The operating margin of -1.59 and net profit margin of 0.57 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -2.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.39, meaning CF PharmTech, Inc. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, CF PharmTech, Inc. Class H has an Altman Z-Score of 25.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.